Edding Genor Group Holdings Limited (HKG:6998)

Market Cap	5.60B
Revenue (ttm)	2.77B -2.3%
Net Income	444.30M
EPS	n/a
Shares Out	2.00B
PE Ratio	12.61
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,099,500
Average Volume	764,025
Open	2.800
Previous Close	2.800
Day's Range	2.730 - 2.850
52-Week Range	1.710 - 5.600
Beta	0.92
RSI	54.73
Earnings Date	Mar 27, 2026

About HKG:6998

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in clinical development for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are in preclinical and early clinical stages. It also provides Van...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 17
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6998

Financial Performance

Financial numbers in CNY